← All organizations
Highest phase reached
Phase 3
Acquired by Horizon Therapeutics, LLC → Amgen on Feb 1, 2021
Timeline
2010s
- Jun 1, 2017
Viela Bio— Founded
2020s
- Jun 11, 2020
inebilizumab— Marketing Organization
- Feb 1, 2021
Horizon Therapeutics, LLC— Acquired By
- Dec 12, 2022
Amgen— Now
Drugs by trial phase (6 distinct, 11 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (3 own, 0 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Arthritis
- Arthritis, Rheumatoid
- Death
- Dermatomyositis
- Immunoglobulin G4-Related Disease
- Lung Injury
- Lupus Erythematosus, Cutaneous
- Lupus Erythematosus, Systemic
- Muscle Weakness
- Myasthenia Gravis
- Polymyositis
- Respiratory Distress Syndrome
- Scleroderma, Diffuse
- Scleroderma, Systemic
- Sclerosis
- Sjogren's Syndrome
- Syndrome
- Wounds and Injuries
Marketed drugs (1)
Recent trials (16)
- NCT04948099Lead sponsorPhase 1Jul 6, 2021
- NCT04925934Lead sponsorPhase 2Jun 24, 2021
- NCT04540497Study directorPhase 3Oct 26, 2020
- NCT04540497Lead sponsorPhase 3Oct 26, 2020
- NCT04524273Lead sponsorPhase 3Aug 30, 2020
- NCT04526912Lead sponsorPhase 1Aug 28, 2020
- NCT04174677Lead sponsorPhase 2Dec 31, 2019
- NCT04163991Study directorPhase 2Dec 2, 2019
- NCT04163991Lead sponsorPhase 2Dec 2, 2019
- NCT04129164Lead sponsorPhase 2Oct 16, 2019
- NCT04046549Study directorPhase 2Aug 30, 2019
- NCT04046549Lead sponsorPhase 2Aug 30, 2019
- NCT03817424Lead sponsorPhase 1Dec 13, 2018
- NCT03817424Study directorPhase 1Dec 13, 2018
- NCT03621605Lead sponsorPhase 1Aug 14, 2018
Details
- Founded
- Gaithersburg, MD, US Jun 1, 2017
- Last known activity
- Jul 6, 2021